Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.

Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform

Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2

U.S.-listed shares of Sanofi gained 0.7% in premarket trading on Wednesday after the company said it has formed a nonprofit business unit that will provide 30 essential medicines to 40 lower-income countries. The creation of Sanofi Global Health is part of the drug maker's corporate social responsibility plan.

Sanofi forms nonprofit unit to provide essential medicines to some low-income countries

PARIS, April 7, 2021 /PRNewswire/ -- In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. Embedded in Sanofi's long-term strategy, the company's commitment is based on four essential pillars in which Sanofi is uniquely positioned to make a difference: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees.

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

GlaxoSmithKline

There are five billion reasons these companies hope it's not.

Is the Market For a Flu Vaccine Disappearing?

Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.

Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion

Johnson & Johnson

Vaxart

Sometimes, the huge potential gains of small biotechs are worth the risk.

These 3 Stocks Will Make You A Fortune If They Succeed

PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy. "In the Phase 3 IKEMA study, the addition of Sarclisa to carfilzomib and dexamethasone reduced risk of disease progression or death by 45%," said Thomas G.

FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Daiichi Sankyo Co Ltd

Though Daiichi Sankyo (OTCMKTS: DSNKY) and Sanofi SA (NASDAQ: SNY) came forward to help produce other pharmas' COVID-19 shots, the companies are calling it quits on their own, separate vaccine alliance in Japan.  Daiichi Sankyo has decided to suspend the Squarekids combination vaccine production and a development deal for the pentavalent combination shot VN-0105 after encountering a manufacturing snag.

Daiichi Axes Sanofi Vaccine Pact After Pertussis Jab Manufacturing Faces Snag

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - February 2021

Sanofi SA (NASDAQ: SNY) is dropping a major investment into its supply chain by shelling C$925 million to build a new manufacturing facility in Toronto. The new facility will be operational by 2026 and provide additional antigen and filling capacity for Fluzone, a high-dose flu vaccine.

Canadian Government, Sanofi To Build C$925M Flu Vaccine Facility In Toronto

AbbVie

Amgen

Bristol-Myers

Gilead Sciences

Eli Lilly

Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.

7 Big Pharmaceutical Stocks for Bigger Income

Adicet Bio, Inc.

Editas Medicine

Immatics NV

Sesen Bio Inc.

Shattuck Labs

LAVA Therapeutics has filed to raise $101 million in an IPO.

LAVA Therapeutics Seeks $101 Million U.S. IPO

Global Blood Therapeutics

Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY). One program pursues a novel anti-sickling mechanism, and the other leverages a new approach to reduce inflammation and oxidative stress.

GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi

Regeneron Pharmaceuticals

Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.

Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer

Telesis Bio Inc

Moderna

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed that they're stopping a Phase 3 cervical cancer trial early after Libtayo showed cutting the risk of death by 31% over chemotherapy. The Independent data monitoring committee unanimously recommended stopping the trial after reviewing the OS data at an interim analysis, thus paving the way for regulatory approval this year.

Regeneron/Sanofi Boast Positive Overall Survival Results In Late-Stage Cervical Cancer Study

Paul Hudson is the CEO of Sanofi. The French pharmaceutical company has two Covid-19 vaccines under development — one with GlaxoSmithKline, the other with Translate Bio for an mRNA vaccine. It's also manufacturing vaccine doses for competitors Johnson & Johnson and Pfizer.

Op-Ed: Sanofi CEO on navigating Covid one year later. Now what?

The two mRNA vaccines licensed for Covid-19 have proven highly effective, according to clinical and real-world studies.

Pharma Giant Sanofi Launches Human Trial Of mRNA Covid-19 Vaccine

Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have started a human trial of their mRNA COVID-19 vaccine candidate, dubbed MRT5500. The event has triggered a milestone payment of $25 million to Translate Bio.

Sanofi, Translate Bio Initiate Human Trial Of mRNA COVID-19 Vaccine Candidate

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

Sanofi (SNY) Presents at Barclays Global Healthcare Conference 2021 (Transcript)

The FDA accepts Sanofi's (SNY) sBLA for review of Dupixent for treating moderate-to-severe asthma in children aged six-11 years. A verdict from the FDA is expected on Oct 21, 2021.

News for Sanofi Stock (SNY)